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Study title: Prevention of Atherosclerosis in Patients Living with HIV.
Phase of study: Phase III.
Aims: Primary aim:
•   To assess whether rosuvastatin therapy could slow the progression of the carotid intima-media 
thickness (C-IMT; as measured by the change in the mean IMT of the near and far walls of 
the distal common carotid arteries) over 2 years in HIV-infected patients (HIV-IP).
Secondary aims:
•    To assess whether rosuvastatin therapy could reduce highly sensitive C reactive protein 
(hs-CRP) inﬂ  ammatory marker that is increased in HIV-IP.
•    To assess the effect of rosuvastatin therapy on serum lipid levels (total cholesterol [TC], 
low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol and 
triglycerides [TG]) and apolipoproteins (APO A1, APO B and APO B/A1).
•    To assess the safety of rosuvastatin in HIV-IP through the evaluation of clinical laboratory 
analyses (liver function tests and creatine kinase) and adverse events (AEs).
Study design: Two-year randomized, double-blind, placebo-controlled, parallel group study.
Planned sample size: 320 HIV-IP.
Summary of eligibility criteria: HIV-IP who are aged between 30 and 60 years, with a 
CD4 count. greater than 200 cells/mm3. Patients must be stable on combination antiretroviral 
therapy (cART) for at least 12 months and have a 10-year CVD risk of less than 20% (using 
the Framingham risk score).
Number of study centers: One.
Duration of treatment: Two years (5 mg rosuvastatin or placebo once daily).
Dose and route of administration: Oral rosuvastatin (5 mg) once daily.
The incidence of cardiovascular disease (CVD) in HIV-IP is at least three times higher than in 
the general population and further increases each year with combination anti-retroviral therapy 
(cART). The carotid atherosclerosis progression rate is 10 times higher in HIV-IP than in uninfected 
individuals. The aim of this study is to assess whether therapy with 5 mg rosuvastatin could:
1)  Slow the progression in the mean IMT of the distal common carotid arteries over two years 
in HIV-IP.
2)  Change the concentration in the inﬂ  ammatory marker – hs-CRP, which is increased in HIV-IP.
3)  Change the concentrations of TC, LDL cholesterol, HDL cholesterol, TG, apolipoproteins 
(APO) B, APO A1 and APO B/A1.
4)  Be administered safely in the study population.
Pharmacological intervention with rosuvastatin will be evaluated in a double-blind, 
placebo-controlled, randomized clinical trial in HIV-IP treated with cART not matching the 
published selection criteria for lipid-lowering therapy. For the ﬁ  rst time, this study will inves-
tigate anti-inﬂ  ammatory and anti-atherogenic effects of a pharmacological lipid-lowering agent 
in HIV-IP that may lead to the reduction of CVD.
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Background information
Introduction
HIV infection and cardiovascular disease risk
Clinicians who treat HIV-infected patients (HIV-IP) are 
increasingly concerned in regard to cardiovascular (CV) risk 
associated with combination antiretroviral therapy (cART).1,2 
HIV-IP have signiﬁ  cant risk factors for the development of 
cardiovascular disease (CVD):
1)  HIV infection and its treatment affect endothelial func-
tion, induce vascular inﬂ  ammation and carotid athero-
sclerosis.3
2)  In HIV-IP high-sensitivity C-reactive (hs-CRP) protein 
concentration is increased and has been shown to predict 
mortality.2
3)  HIV and its treatment are associated with pro-atherogenic 
dyslipidemia,1 which is an important risk factor for the 
development of CVD.4
4)  The Framingham risk equation underestimates the risk 
of developing CVD in HIV-IP.5
5)  HIV infection is associated with a state of chronic imm une 
activation6 that persists in patients on cART who achieve 
suppression of viral replication.7
6)  CVD is the fourth cause of death in HIV-IP.1
The best evidence linking HIV infection and its treatment 
to increased CV risk comes from the D:A:D cohort, a large epi-
demiological study that combined data from several primary 
care clinics in Europe and the United States. The D:A:D study 
demonstrated an increased incidence of myocardial infarction 
and CV events in HIV-IP who were receiving cART.8,9 The 
incidence of coronary heart disease in HIV-IP is at least three 
times the incidence in the general population and increases 
with increasing exposure to cART.10 Lipid-lowering therapy 
has been shown to reduce CV events in a large number of 
studies;11–13 however there are no data available in HIV-IP.
Atherosclerosis in patients living 
with HIV – State of Science Conference in 2007
Scientists and healthcare providers convened in June 2007 for 
the ‘State of the Science Conference: Initiative to decrease 
cardiovascular risk and increase quality of care for patients 
living with HIV/AIDS’, a joint effort of the American Heart 
Association (AHA) and the American Academy of HIV 
Medicine. The conference proceedings are published online 
in Circulation, the Journal of the American Heart Association 
and the Journal of Acquired Immune Deﬁ  ciency Syndrome.14 
Among the group’s key ﬁ  ndings:
1)  Clinical trials focusing on atherosclerosis prevention that 
speciﬁ  cally target HIV patients are much needed. In order 
to achieve progress in the prevention of CV complications 
of HIV, important gap areas in our knowledge need to be 
clearly spelled out and targeted for further research.
2)  The rate of progression of carotid intima-media thickness 
(C-IMT) over time is valuable in determining cardiovas-
cular risk in HIV-IP.
3)  The risk for heart attack is 70% to 80% higher among people 
with HIV compared to those who do not have HIV.
4)  Use of agents for lipid lowering may improve individual 
CV risk in the HIV population.
5) Newer  inﬂ  ammatory biomarkers, such as hs-CRP may prove 
useful for identifying infected patients at risk for CVD (of 
the biomarkers only hs-CRP has been recommended for use 
in clinical practice by CDC and prevention and the AHA).
HIV antiretroviral therapy and cardiovascular 
disease risk
The current cART regimens include two nucleoside reverse 
transcriptase inhibitors (NRTI) in combination with either a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) or 
a boosted protease inhibitor (PI).15 Antiretroviral therapy has 
been associated with lipid metabolism disorders and insulin 
resistance increasing the risk of CV disease.16 Results from 
clinical trials suggest that most PIs increase both triglycerides 
(TG) and total cholesterol (TC). Approximately 30% to 40% 
of HIV-IP starting boosted PI-containing regimens show an 
increase in TG and TC at 48 weeks.16 The mechanisms by 
which HIV infection and cART cause lipid dysregulation are 
not fully elucidated and many investigations are currently 
underway. However, the association between cART and the 
risk of myocardial infarction is obvious.17–21 The International 
Forum for Collaborative HIV research has thus highlighted 
the need to identify and manage HIV-IP at increased risk of 
developing CVD.22
Progression of atherosclerosis as assessed 
by C-IMT in HIV-IP
Measurement of C-IMT with high-resolution B-mode 
ultrasound is a well-accepted, noninvasive method of assessing 
atherosclerosis and tracking its progression. C-IMT measure-
ments correlate well with pathological measurements23 and 
are potent predictors of myocardial infarction and stroke, 
even after adjustment for other risk factors.24–26 Progression 
of C-IMT can be measured reliably over time27 and has been 
used as an endpoint in clinical trials in which treatment reduced 
both C-IMT progression and CV events.28
Carotid B-mode ultrasound has been used in several studies 
to assess atherosclerosis in HIV-IP. Maggi et al reported that Vascular Health and Risk Management 2009:5 289
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carotid plaques were more common in 55 patients receiving 
PI than in 47 PI-naïve patients.29 In a larger series, investiga-
tors from the Swiss HIV Cohort Study found that carotid and 
femoral artery plaques were associated with classic coronary 
risk factors and not with PI use.30 Seminari et al found that 
carotid IMT was increased in 28 HIV-IP receiving PI com-
pared with measurements in 15 PI-naïve patients and 16 
HIV-negative subjects.31 Chironi et al reported that 36 HIV-IP 
receiving PI had C-IMT equal to that of non-HIV subjects 
with similar lipid and glucose disturbances;32 both groups 
had increased C-IMT compared with control subjects with-
out lipid and glucose abnormalities. In another study of 423 
HIV-IP, conventional risk factors but not lipodystrophy or 
cART were independent predictors of increased C-IMT.33
The ﬁ  ndings of Hsue et al indicated that HIV-IP have 
greater C-IMT compared with age- and sex-matched control 
subjects.5,34,35 Furthermore, the rate of progression of C-IMT 
in HIV-IP of ∼0.074 mm/year was several-fold higher than the 
rate of ∼0.006 mm/year reported in non–HIV-IP. Of interest, in 
45 of the 121 HIV-infected patients (or HIV-IP) (37%), mean 
carotid C-IMT progressed by  0.10 mm/year.5
Because increasing C-IMT is an independent predictor of 
stroke and myocardial infarction in other populations,24–26 the 
ﬁ  ndings of Hsue et al study suggest that the rate of vascular 
events is likely to increase substantially in HIV-IP.5 The patho-
genesis of accelerated atherosclerosis in HIV-IP has not been 
adequately studied, and the degree to which classic coronary 
risk factors are responsible, as opposed to HIV-related factors 
and factors related to treatment, is not known. Additional 
studies with longer follow-up are needed to determine the 
cause of accelerated atherosclerosis in HIV-IP.
Impact of statins on structural and functional 
changes of the vasculature in HIV-IP
C-IMT is considered to be an objective marker of early 
atherosclerosis.5 It has been demonstrated that C-IMT is a 
reliable indicator for studying the long-term effects of anti-
retroviral treatment, but systematic longitudinal observations 
are scarce. The only longitudinal study in HIV-IP found 
C-IMT progression rate to be 10 times higher in the treatment 
group than the control group,5 suggesting that both traditional 
risk factors and the PI therapy were affecting atherosclerosis. 
The mean C-IMT was 0.90 ± 0.27 mm higher than expected 
from a large population study of similarly aged individuals. 
The mean progression rate was 0.1 ± 0.1 mm/year, which was 
greatly accelerated compared to 0.01 ± mm/year from pub-
lished report of non-HIV-IP. Recently Charakida et al have 
demonstrated that HIV infection in childhood is associated 
with adverse structural and functional vascular changes that 
are most pronounced in children exposed to PI therapy.36 
Yu et al documented that statin-therapy signiﬁ  cantly reduced 
C-IMT and inﬂ  ammatory markers in patients with CVD in 
26 weeks.37 The Meteor study demonstrated the efﬁ  cacy of 
rosuvastatin in reducing progression of C-IMT (over 2 years) 
in a randomized clinical trial in low risk individuals with 
subclinical atherosclerosis.38
Rosuvastatin and C-IMT changes
A 19% reduction in coronary mortality has been recorded 
per 1.0 mmol/L (38.7 mg/dL) decrease in LDL cholesterol.39 
Statins also have been shown to slow the progression of 
and even regress atherosclerosis.40 This has been demon-
strated in coronary atherosclerosis by quantitative coronary 
angiography, intravascular ultrasound and carotid athero-
sclerosis by B-mode ultrasound measurement of C-IMT.41–45 
Most clinical trials of lipid-lowering efﬁ  cacy have shown that 
lowering lipid levels is beneﬁ  cial irrespective of baseline LDL 
cholesterol level. However, the majority of such trials have 
been performed in high-risk populations, in individuals with 
high lipid concentrations or in patients with existing CVD but 
not in those with HIV/AIDS. Rosuvast atin is effective in low-
ering LDL cholesterol concentrations.46,47 Rosuvastatin also 
has favorable effects on other components of the lipid proﬁ  le, 
raising HDL cholesterol and reducing TC and TG.48
Involvement of hs-CRP in atherogenesis
A number of biomarkers that appear to be linked to inﬂ  am-
mation and atherogenesis have been identiﬁ  ed and hs-CRP 
has attracted particular attention. Plasma hs-CRP has a long 
half-life, exhibits stable concentrations in individuals, has 
negligible circadian variation and can be easily measured. 
As a downstream biomarker, hs-CRP provides a functional 
integration of overall upstream cytokine activation and 
exhibits activities that may initiate and stimulate progression 
of vascular disease, including the binding and activation of 
complement. It has also been shown that high concentra-
tion of plasma hs-CRP is associated with elevated levels 
of cell adhesion molecules (CAMs) and tissue factor, LDL 
cholesterol uptake by endothelial macrophages. Moreover, 
it induces the recruitment of monocytes into blood vessel 
walls and increases the levels of monocyte chemoattractant 
protein-122. hs-CRP has been widely considered as a predic-
tor of CVD.49,50 The currently recommended plasma hs-CRP 
cut points are  1.0 mg/L for low risk, 1.0 to 3.0 mg/L for 
average risk, and  3.0 mg/L for high risk.50 Accumulating 
evidence suggests that inﬂ  ammatory markers like hs-CRP Vascular Health and Risk Management 2009:5 290
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may provide an adjunctive method for global assessment 
of CV risk. Recent data suggest several biological effects 
are mediated through hs-CRP activation of nuclear factor-
kappa B (NF-κB):51
1)  Up-regulation of chemokines that promotes neutrophil 
and monocyte endothelial cell adhesion (IL-8), monocyte 
chemotaxis and recruitment (MCP-1).
2)  Up-regulation of key regulator of ﬁ  brinolysis by inhibiting 
tissue plasminogen activator (PAI-1).
3)  Up-regulation of soluble CAMs that activate monocyte 
adhesion to endothelium (ICAM-1, VCAM-1).
4) Up-regulation of the primary initiator of the serine 
protease cascade of the coagulation system promoting 
thrombosis (Tissue Factor). Although these effects are 
important in atherogenesis, they clearly contribute to 
the genesis of acute coronary syndrome by recruiting 
leukocytes and promoting thrombosis.
hs-CRP in HIV-IP
Hsue et al reported that HIV-IP have higher hs-CRP levels 
than controls.52 The median hs-CRP level was 1.6 mg/L 
in HIV-IP compared to 0.7 mg/L in controls (p = 0.001). 
Approximately 10% of HIV-IP had hs-CRP greater than 
10 mg/L.52,53 Noursadeghi suggested that the increased 
hs-CRP is the consequence of HIV infection per se.54 
Feldman et al reported that hs-CRP may be a useful and 
inexpensive predictor of HIV disease mortality in women.55 
Lau et al obtained a single measurement of hs-CRP from 
513 HIV-infected men in a multicenter AIDS Cohort Study 
to examine the association between hs-CRP and immune 
suppression and progression to AIDS.56 In this study, con-
centrations of hs-CRP were associated with HIV disease 
progression independent of CD4 lymphocyte counts and 
HIV RNA levels. In addition, regardless of progression to 
AIDS, HIV-IP had a signiﬁ  cant increase in hs-CRP over time. 
hs-CRP levels tended to be quite high in HIV-IP, even with 
virological suppression to  50 copies/mL over 3 years.7 
Therefore, increased hs-CRP has signiﬁ  cant implications 
for CVD in HIV-IP.56 On the basis of the available evidence, 
the Centers for Disease Control (CDC)/AHA suggest that 
patients with moderate risk (10% to 20% risk of CVD over 
10 years) may beneﬁ  t from measurements of hs-CRP to 
Table 1 Detailed breakdown of screening visits
Pre-screening 
visit
Baseline 
visit
Follow-up
Time (days) 28 to 14 days 
earlier
Day 1 Month 2 Month 6 Month 12 Month 18 Month 24
Informed consent X
Demographic data X
Medical history/concomitant disease X
Physical examination X X X X X X
Vital signs X X X X X X
ECG X X X X X X X
Weight X X X X X X
Height X
Urinalysis1 XX X
Hematology2 XX X X X X X
Clinical chemistry3 XX X X X X
Vascular inﬂ  ammation marker4 XX X X X
C-IMT5 XX X X X
Adherence questioning and compliance check X X X X
Adverse events X X X X X X
Drug dispensing X X X X
Concomitant medication check X X X X X X X
1Urinalysis including drug screen and pregnancy test (female subjects).
2With a differential and clotting screen.
3Fasting for at least 10 hours and including creatinine, urea, potassium, sodium, bicarbonate, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein 
cholesterol, triglycerides, calcium, phosphate, liver function tests (ALT, AST, GGT), albumin, glucose, amylase and C-reactive protein (CRP).
4Vascular inﬂ  ammation marker highly sensitive CRP (hs-CRP).
5Carotid ultrasound – C-IMT measurement.Vascular Health and Risk Management 2009:5 291
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identify individuals who should be considered for medical 
therapy.14
Pharmacological anti-inﬂ  ammatory effect of statins
Evidence from clinical trials: Large clinical trials, such as 4S, 
WOSCOPS, CARE, LIPID, AFCAPS/TexCAPS, ASCOTT-
LLA and HPS, provided unequivocal evidence that statins 
reduce CV mortality and non-fatal vascular events.57–59 
The most compelling clinical data relating statin therapy to 
anti-inﬂ  ammatory mechanisms is derived from studies of 
inﬂ  ammatory biomarkers, such as C reactive protein (CRP).59 
Individuals with elevated CRP ( 3 mg/L) are at increased 
risk for ﬁ  rst, as well as recurrent, CV events independent 
of lipid levels and disease severity as determined by global 
risk-assessment tools such as the Framingham Risk Score 
(FRS).60 Multiple studies have demonstrated that statins as 
a class lower median CRP level by 15% to 35% in a manner 
largely independent of plasma lipid reduction.57,58 Patients 
who have low CRP levels after statin therapy have better 
clinical outcomes than those with higher CRP levels, regard-
less of the resultant level of LDL cholesterol.59 The effect of 
statin therapy may result from:61,62
1)  Actions dependent on lipid alterations.
2)  Actions independent of lipid alterations but dependent on 
inhibition of HMG-CoA reductase, such as that resulting 
from cellular mevalonate depletion.
3)  Distinct combinations of the above actions.
At present, there are no data available on the efﬁ  cacy of 
CVD primary prevention with lipid-lowering therapy (eg, 
statins) in HIV-IP. In addition, no clinical trials have yet been 
designed to evaluate the possibility that lipid-lowering agents 
may interfere with inﬂ  ammatory activity and early vascular 
remodelling taking place in HIV-IP. HIV-IP (at increased 
risk of developing CVD) with lipid metabolism disorders 
are, therefore, still assessed and treated in accordance to the 
global risk-assessment tools, such as the FRS used for the 
general population.60 There is, therefore, an urgent clinical 
need to identify the strategy for a beneﬁ  cial primary preven-
tion (lipid-lowering-agent therapy) in HIV-IP.
Mechanisms of action of statins
Depletion of intracellular mevalonate inhibits the formation 
of isoprenoids, farnesyl-pyrophosphate and geranylgeranyl-
pyrophosphate, and thus prenylation of many cell-signaling 
proteins.63 Prenylation is the attachment of isoprenoids to 
proteins, a process which is necessary for insertion and 
anchorage of proteins to cell membranes for the full biologi-
cal function. Rho is a small GTPase protein that mediates 
activation of the pro-inﬂ  ammatory transcription factor NF-
κB required for monocyte adhesion to endothelial cells.64 
Statins, through mevalonate depletion and prevention of 
prenylation, ultimately prevent monocyte and endothelial 
interaction and reverse the above inﬂ  ammatory processes 
associated with atherosclerosis.64 Plaque rupture and sta-
bilization has also been related to mechanisms that include 
modulation of NF-κB and decrease prenylation of small 
signaling Rho proteins.65,66 NF-κB normally resides in the 
cytoplasm bound to its inhibitor (IκB). In response to inﬂ  am-
matory stimuli, IκB is phosphorylated and degraded thereby 
liberating NF-κB to translocate to the nucleus and induce 
the expression of target genes.65 Statins have been shown to 
limit NF-κB nuclear accumulation and DNA binding, perhaps 
via an increase in the expression of IκB.50 NF-κB regulates 
expression of both adhesion molecules (eg, VCAM-1) and 
selectins (eg, E-selectin)58 being responsible for up-regulation 
of the inﬂ  ammatory cytokines. Recent studies suggest that a 
second mechanism by which statins confer favorable proper-
ties to the endothelium is through the induction of nuclear 
factors, such as Kruppel-like factor 2 (KLF2) and peroxi-
some proliferators-activated receptors (PPARs).67,68 It has 
been found that sustained expression of KLF2 induces key 
factors, such as thrombomodulin, and inhibits the cytokine-
mediated activation of pro-adhesive, prothrombotic factors 
(for example VCAM-1).69,70 The ability to inhibit endothelial 
pro-inﬂ  ammatory activation by KLF2 is due to inhibition 
of NF-κB transcriptional activity.70 The mutual antagonism 
between NF-κB and KLF2 might, therefore, serve as key 
mechanism by which endothelial health is regulated. Of inter-
est, multiple statins can induce KLF2 expression.71 PPARγ 
and PPARα – that have been identiﬁ  ed in vascular cells and 
shown to possess potent anti-inﬂ  ammatory properties (in 
part via inhibition of NF-κB) – can be augmented by statin 
treatment.72,73 The early clinical beneﬁ  ts from lipid-lowering 
therapy are attributed to the plaque-stabilizing properties of 
statins, mediated through a combined reduction in lipids and 
macrophages.57
Rationale and need for the current study
In view of the present situation, strategies to estimate the 
association between HIV disease, cART and CV risk could 
take a direct or indirect approach. A direct approach would 
compare CVD rates or CVD markers within or between 
large populations. For example a study to determine whether 
statin therapy will lower the risk of CVD in people with 
antiretroviral-induced lipid elevations would require several 
thousand people followed for several years and would cost Vascular Health and Risk Management 2009:5 292
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US$200 million or more, according to the International 
Forum for Collaborative HIV research. Indirect strategies 
(recommended by the Forum for Collaborative HIV research) 
to estimate the association between cART and CVD risk 
could estimate the effect of anti-retrovirals on risk factors 
and surrogate markers for CVD. As long as the questions 
asked by a surrogate marker study are clear, the markers 
to be included and the biology behind these markers have 
to be considered carefully. CVD markers should measure 
endothelial function, inﬂ  ammation and macrophage acti-
vation. This study will produce evidence for the need of a 
more aggressive primary prevention approach in HIV-IP. 
The current identiﬁ  cation of patients, in need of treatment, 
is not satisfactory in view of the fact that within the same 
age range the HIV-IP are at higher risk of developing CVD 
compared to the general population.
Our study has been carefully designed to address a crucial 
unanswered question regarding HIV infection, cART, progres-
sion of carotid atherosclerosis, statins and CVD, as follows:
Will statin therapy prevent progression of C-IMT over 
2 years in HIV-IP? This issue is of exceptional clinical impor-
tance in accordance to the International Forum for Collabortaive 
HIV Research and the recent statements from a group of experts 
in HIV/CVD published by Circulation in June 2008.2,22 In fact, 
progression of C-IMT in HIV-IP is 10 times higher than in unin-
fected individuals. Thus, a strong positive ﬁ  nding from this study 
will dramatically affect prevention and would provide a clear 
rationale for much broader use of statin therapy for the primary 
prevention of CVD events than currently endorsed. On the other 
hand, a negative ﬁ  nding would also be of great importance, as 
it would direct the use of scarce prevention resources to other 
non-statin methods for CVD reduction. By using rosuvastatin, 
this study will also be addressing whether LDL-cholesterol 
reduction has efﬁ  cacy in primary prevention among those indi-
viduals that do not match the Joint British Societies’ Guidelines 
on Prevention of Cardiovascular Disease in Clinical Practice 
(JBS2) criteria for lipid-lowering therapy.74
Rationale for the use of rosuvastatin
Clinically relevant drug-drug interactions have been 
reported between commonly used NNRTIs (inducers of 
cytochrome P450 [CYP450] – mainly the isoforms 3A4 
and 2B6) or ritonavir-boosted PIs (inhibitors of CYP450 – 
mainly 3A4). Rosuvastatin, however, is not extensively 
metabolized; approximately 10% of a radiolabelled dose 
is recoverable as a metabolite. The major metabolite is 
N-desmethyl rosuvastatin, which is formed principally 
by CYP450 2C9. Nevertheless, unexpected drug-drug 
interactions have been observed between lopinavir/ritonavir 
in both HIV-IP75 and healthy volunteers.76 While lopinavir/
ritonavir concentrations are not affected by rosuvastatin 
co-administration, an approximate 1.6- to 4-fold increase in 
rosuvastatin exposure has been observed in the presence of 
lopinavir/ritonavir. Rosuvastatin is safe when administered 
at 5 mg once daily to patients on boosted PI and higher 
doses should be avoided. Studies are needed to elucidate 
the mechanism for this interaction.
AIM(S)
“Rosuvastatin slows progression of carotid atherosclerosis 
(C-IMT) by down-regulating inﬂ  ammation in plasma (as 
assayed by plasma hs-CRP).”
Primary aim:
•  To assess whether rosuvastatin therapy could slow the 
progression of the C-IMT (as measured by the change 
in the mean IMT of the near and far walls of the distal 
common carotid arteries) over two years in HIV-IP.
Secondary aims:
•  To assess whether rosuvastatin therapy could reduce 
hs-CRP inﬂ  ammatory marker that is increased in HIV-IP
•  To assess the effect of rosuvastatin therapy on serum 
lipid levels (TC, LDL cholesterol, HDL and TG) and 
apolipoproteins (APO A1, APO B and APO B/A1)
To assess the safety of rosuvastatin in HIV-IP through 
the evaluation of clinical laboratory analyses (liver function 
tests and creatine kinase) and adverse events.
Expected value of the results
The number of people living with HIV worldwide has been 
estimated to be 40 million in 2006 (of these 740,000 are in 
Western and Central Europe) – 8000 die and 12,000 become 
infected every day.77 In 2006, 4.3 million (22,000 in Western 
and Central Europe) people were newly infected with HIV. 
cART has altered the nature of HIV disease, converting a 
lethal illness into a chronic and stable condition. Despite 
the beneﬁ  ts of cART, its use is complicated by a number of 
factors, including the risk for CVD, side effects, drug-drug 
interactions and the selection of drug-resistant virus. In 2003 
the international Forum for Collaborative HIV research 
issued guidelines to develop new strategies with the goal to 
prevent CVD. Members of the Forum are well recognized 
clinical and research leaders in HIV medicine. Their work 
has clearly identiﬁ  ed the urgent need to respond, in the ﬁ  rst 
instance to the increased risk of CVD in HIV-IP, and to the 
concern expressed regarding increasing CVD risk with the Vascular Health and Risk Management 2009:5 293
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aging of the HIV-IP. This study should demonstrate for 
the ﬁ  rst time the:
1)  Pharmacological anti-atherogenic and anti-inﬂ  ammatory 
effects of statin therapy in HIV-IP.
2)  Evidence to reconsider the lipid-lowering therapeutic 
criteria presently used (JBS2) in HIV-IP.
Trial design
Trial overview
Design of the proposed clinical investigation is as follows. 
This randomized, double-blind, placebo-controlled, parallel 
group study is aimed at investigating the effect of rosuvastatin 
on vascular inﬂ  ammation/dysfunction in HIV-IP (n = 320). 
At present, no large trials have presented data on the impact 
of reducing LDL cholesterol in HIV-IP; therefore the 
lipid-lowering recommendations for the general population 
are applied to the HIV-IP. We propose to include in the 
C-IMT study HIV-IP that do not already match published 
selection criteria for lipid-lowering therapy.74 Following writ-
ten consent and screening procedures, eligible patients will 
be randomized on study day 1 either to receive rosuvastatin 
5 mg once daily (ARM 1) or placebo once daily (ARM 2). 
Rosuvastatin or placebo will be administered for 2 years.38 
Carotid ultrasound to measure the change in C-IMT, safety 
laboratory tests, lipid proﬁ  les, apolipoproteins, immunological 
and virological response markers and an inﬂ  ammatory marker 
(hs-CRP) will be assessed at baseline (before rosuvastatin or 
placebo initiation), following 6 months, 12 months (study 
day 365), 18 months (study day 547) and 24 months (study 
day 730) of therapy. On study day 730, ARM 1 and ARM 2 
subjects will stop rosuvastatin/placebo intake. The rationale 
for the 24-month duration of rosuvastatin therapy is in accor-
dance with the International Guidelines for the Treatment 
of HIV Infection,10 which report that hyperlipidemia occurs 
weeks to months after beginning of CART.
Inclusion criteria
1)  Documented HIV infection.
2)  HIV-IP with a CD4 count   200 cells/mm3, who, according 
to the International Guidelines for the Treatment of HIV 
Infection, are stable on cART for at least 12 months.
3) Viral  load   50 copies/mL.
4)  Aged 30 to 60 years.
5)  Asymptomatic for any atherosclerosis-related disease.
6)  10-year CVD risk   20% (using the JBS 2 criteria).74
Exclusion criteria
1)  Pharmacological lipid-lowering therapies (eg, statins, 
ﬁ  brates.) in the 12 months before the ﬁ  rst visit.
2) Clinical evidence of coronary heart disease, angina, 
myocardial infarction, stroke or other peripheral athero-
sclerotic disease.
  3)  Previous revascularization procedures.
  4)  10-year CVD risk   20% (JBS 2 criteria).
  5)   Diabetes mellitus, uncontrolled hypertension or familial 
hypercholesterolemia.
 6)   Serum creatinine levels of  177 pmol/L during 
screening.
  7)   Active liver disease or elevated liver enzymes (ALT   3 
times upper limit of normal [ULN]).
 8) Creatine  kinase   3 times ULN.
  9)  History of cancer.
10)   Chronic  inﬂ  ammatory conditions, such as severe arthri-
tis, lupus or inﬂ  ammatory bowel disease.
11)  Alcohol or drug abuse within the past year.
12)   Serious medical or psychological conditions that may, in 
the opinion of the investigator, compromise successful 
study participation.
13) Uncontrolled  hypothyroidism.
14)  Current use of immunosuppressants.
15)    Current use of post-menopausal oral hormone therapy.
ARM 2 (n = 160)
Placebo 
6 months 
12 months 
18 months 
24 months 
ARM 1 (n = 160)
Rosuvastatin 5 mg 
Baseline
HIV-infected patients + 
cART (n = 320)  
Figure 1 Protocol design for C-IMT assessment and hs-CRP measurement.Vascular Health and Risk Management 2009:5 294
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16)    Current use of cART containing less than two different 
classes of antiretroviral agents.
17)  Evidence of focal plaques (carotid ultrasound).
Duration of involvement
The total duration of involvement in the study is 730 days, 
with a screening visit within 28 days prior to rosuvastatin/
placebo commencement at day 1 and follow-up visits at 2, 
6, 12, 18 and 24 months.
Withdrawal of patients 
and discontinuation criteria
Criteria for premature withdrawal
Subjects have the right to withdraw from the study at any 
time and for any reason. The investigator may also withdraw 
subjects from the study or decide to discontinue medication 
dosing in the event of inter-current illness, adverse events, 
protocol violations, administrative reasons or other reasons. 
An excessive rate of withdrawals can render the study 
uninterpretable. As a result, the unnecessary withdrawal of 
subjects should be avoided.
In all cases of withdrawal, the date and reasons for the 
withdrawal or discontinuation of medication will be clearly 
stated on the subject’s case report form (CRF). If the reason 
for removal of a subject from the study is an adverse event 
or an abnormal laboratory test result, the principal speciﬁ  c 
event or test will be recorded on the CRF.
Withdrawn subjects may be replaced at the discretion of 
the investigator.
Follow up of abnormal laboratory 
test values
In the event of unexplained abnormal laboratory test values, 
the tests will be repeated and followed up until they have 
returned to the normal range and/or an adequate explana-
tion of the abnormality is found. If a clear explanation is 
established it should be recorded on the CRF.
Intervention(s) or method
Outlined below is the experimental work for the four differ-
ent clinical trial aims:
Aim 1: C-IMT at different time points 
over 2-years treatment
B-mode ultrasound method: Standardized longitudinal B-mode 
images will be obtained of the near and far walls of the distal 
common carotid arteries and reported as the average value for 
the bilateral measurements. This location was chosen a priori 
because of its demonstrated reproducibility campared with 
C-IMT at other sites.25,78,79 A commercially available ultrasound 
system with comprehensive vascular applications will be used. 
All images will be acquired and stored digitally, and analyzed 
off-line by an independent sonographer who is blinded from 
patient’s information. Color duplex ultrasound scanning will 
be performed with a 7 to 10 MHz linear-array transducers 
and settings adjusted to get an optimal picture of the carotid 
walls. The carotid arteries will be scanned transversely and 
longitudinally. Color ﬂ  ow mapping (“Angio”) will be used to 
identify the bifurcation, the ﬂ  ow divider and localized small 
plaques along the course of the common carotid artery, carotid 
bulb and internal carotid artery on both sides.
The IMT of both far and near walls will be measured with 
magniﬁ  ed pictures frozen at the R wave on the ECG. The 
IMT is deﬁ  ned as the distance between the leading edge of 
the luminal echo to the leading edge of the media/adventitia 
echo. It will be measured over a length of 10 mm immediately 
distal to the ﬂ  ow divider. This will be accomplished by the 
use of the calipers and the trace function of the ultrasound 
system and calculation of the mean IMT over this length. The 
distal common carotid arteries will be assessed in the segment 
extending from 10 to 20 mm proximal the carotid bifurcation. 
All ultrasound scans will be carried out with standardized 
settings. The image boundaries will be marked manually. 
For C-IMT measurements, trailing edges will be traced on 
the near wall boundaries and leading edges on the far wall 
boundaries. Measurements will be performed on images from 
selected angles, 60°, 90°, 120°, 150° and 180° for the right 
carotid artery and 300°, 270°, 240°, 210° and 180° for the left 
carotid artery. Measurements will be made of both the mean 
and maximum C-IMT of each wall at all selected angles. Both 
mean and maximum IMT will be calculated and analyzed. Any 
plaques will be excluded from the measurements. Intraopera-
tor and interoperator variability will be assessed by means of 
coefﬁ  cients of variation. The mean length of the C-IMT will 
be evaluated in both the rosuvastatin and placebo groups. 
The precision and reliability of the ultrasound method will 
be tested in a randomly selected subgroup of 32 arteries with 
paired images obtained on the same day. Carotid ultrasound to 
measure C-IMT will be performed at baseline (before therapy 
with lipid lowering) and after 6, 12, 18 and 24 months.
Aim 2:   Vascular inﬂ  ammation by measuring plasma 
hs-CRP in HIV-IP treated with cART
There are currently no deﬁ  nitive data on the effect of statins 
on hs-CRP in patients HIV-IP. HIV-IP will be advised not Vascular Health and Risk Management 2009:5 295
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to take any platelet inhibiting drugs for a week before blood 
sample collection, which is taken before breakfast. Venous 
blood drawn in a Vacutainer (no more than 30 minute wait) 
is processed and divided into aliquots (plasma or serum if not 
anticoagulated) and frozen at −70 °C for later analysis. hs-CRP 
will be assessed in stored frozen blood samples from baseline, 
6, 12, 18 and 24 months according to methods described by 
the manufacturer of CRP Latex HS (Roche).
Aim 3: Serum lipid levels and apolipoproteins 
in HIV-IP treated with cART
Blood samples will be taken at speciﬁ  c visits to monitor 
serum lipid and apolipoproteins levels (TC, HDL choles-
terol, LDL cholesterol, TG, HDL/TC ratio, APO B, APO 
A1, APO B/A1).
Aim 4: Safety
Safety will be assessed by the evaluation of clinical laboratory 
analysis (such as creatine kinase, creatinine, alanine/aspartate 
aminotransferase, alkaline phosphatase, total bilirubin, 
albumin and fasting blood glucose), hematology and adverse 
events (AEs).
How subjects are randomized 
and how allocation is concealed
The randomization list of the study will be prepared in sealed 
envelopes and handed to a pharmacist. In addition, further 
emergency un-blinding envelopes will be prepared in sealed 
envelopes and given to a lead pharmacist in the unit where the 
trial is conducted who would keep these secure from study 
PI, study co-investigators and the study pharmacist.
The emergency un-blinding sealed envelopes would be 
kept securely and these envelopes would only be opened in 
the event of an emergency to reveal details of the study arm 
of individual subjects recruited to the trial.
In addition once the sealed envelope is opened a strip 
inside the envelop will contain details of ‘Subject Number’ 
and the study group the subject should be allocated. This ‘Sub-
ject Number’ will, therefore, be assigned in the study CRF 
pages from baseline visit onwards, including allocating this 
number in any additional data for the study, such as printed 
copies of laboratory results. This number will, therefore, serve 
and be used to track patient data during the study.
Primary and secondary endpoints
Primary endpoint
To assess whether rosuvastatin therapy could slow the 
progression of the C-IMT (as measured by the change in the 
mean IMT of the near and far walls of the distal common 
carotid arteries) over 2 years in HIV-IP.
Secondary endpoints
•  To assess whether rosuvastatin therapy could reduce 
hs-CRP inﬂ  ammatory marker that is increased in HIV-IP.
•  To assess the effect of rosuvastatin therapy on serum 
lipid levels (TC, LDL cholesterol, HDL and TG) and 
apolipoproteins (APO A1, APO B and APO B/A1).
Safety variables
Safety and tolerability will be monitored by evaluating the 
incidence and severity of AEs and abnormal laboratory values 
(hematology and clinical chemistry).
Statistical analysis plan
Sample size and power calculations
The findings of Hsue et al indicated that HIV-IP have 
greater C-IMT compared with age- and sex-matched control 
subjects.5,34,35 Furthermore, the rate of progression of C-IMT 
in HIV-IP of 0.074 mm/year was several-fold higher than the 
rate of 0.006 mm/year reported in non-HIV-infected subjects. 
Of interest, in 45 of the 121 HIV-IP (37%) the mean carotid 
C-IMT progressed by 0.10 mm/year.5
Based on published data,80 assuming an overall progres-
sion rate between the control and the active arms at year 1 
since entry to study are 0.045 and 0.030 mm, respectively. 
Assuming the rate of progression rate will remain constant at 
year 2 after entry to the study, the mean progression rate in 
IMT is expected to be 0.09 (SD 0.08) mm in the control arm 
while that in the active arm it is expected to be 0.0054 mm. 
This assumes that a 40% difference will be observed between 
arms at 2 years post study, which allows for greater variations 
in the active arm at year 2 compared to year 1 and standard 
deviation is estimated at 0.072. Based on these assumptions 
and assuming 30% of the subjects recruited to the study will 
drop out by year 2, n = 160 subjects per arm (total number 
of study subjects n = 320) will need to be recruited in order 
to show the effect size of this magnitude to be signiﬁ  cantly 
different at 1% level of signiﬁ  cance with 90% power using 
two-sided test. Type I error rate is set at 1% since one interim 
analyses is planned at year 1.
Statistical tests
The primary objective of this study is to assess the effect 
of lipid-lowering drug on the change in the C-IMT from 
baseline to 2 years post entry to study by two study arms. 
The primary endpoint is to assess the change in C-IMT from Vascular Health and Risk Management 2009:5 296
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baseline to study time points in the rosuvastatin and placebo 
arms. All patients who meet the inclusion criteria at baseline 
will form part of the statistical analysis. Data will be ana-
lyzed and presented as both on treatment and intent-to-treat 
(ITT) methods.
All summary statistics will be presented with point 
estimates, which are mean changes from baseline to study 
time point and indication of the variability in data, such as 
the standard deviation or the standard error. All missing 
data at each study visits will be presented and categorized 
as: patients off trial, patients who did not attend, and data 
missing even though patient had attended for their scheduled 
study visit. Where data are missing for such patients these 
will be grouped into missing data.
The ITT method approach that will be undertaken when 
summarizing the data will be the last observation of C-IMT 
carried forward (LOCF) if data are unavailable at the time 
point. The ITT method will be used to describe the data and 
presented with relevant point estimates and 95% CI. This will 
be presented for each study visits from baseline to 2 years 
or end of study.
Although this method is frequently used in data analyses of 
clinical trials, subject drop out rates and patterns (reasons for 
missing data) in clinical trials may be affected by many factors, 
such as the disease, study population, efﬁ  cacy of treatment, 
side effects and length of trial. Often the missing data are com-
pletely random. Carrying forward observations may confound 
treatment with time. This confounding can bias estimates of 
differences between treatment groups in mean change from 
baseline to endpoint and the associated SE leading to inac-
curate assessment of type I and type II error rates. MIXED 
model analyses are more robust to potential bias from missing 
data than LOCF. Estimates of effects based on MIXED models 
assume that any missing data are random.
In addition to the ITT method described above, longitu-
dinal data of the C-IMT will be available and linear mixed 
models will be used between treatment group comparisons 
to calculate the difference in averages (DAVG), which will 
represent the time weighted difference in the C-IMT from 
baseline to each study time point and where deemed neces-
sary data will be transformed to stabilise the variance.
MIXED procedure in SAS will be used by ﬁ  tting values 
of the C-IMT from all study time points as a dependent vari-
able. Independent variables will include the ﬁ  xed effects of 
the intervention arms rosuvastatin and placebo, study visit 
time points and intervention by study time points interac-
tion. A covariance matrix will be used to model the within 
patient errors.
Estimates of change in C-IMT from baseline will be 
obtained from intervention by study time points interaction.
In addition, this method will be used to analyze the effects 
of changes in antiretroviral treatment prescription patterns 
over time, which will be added as time varying covariate in 
the MIXED model.
Trends over time will be presented as point estimates with 
95% CI. Further multivariable analyses will be adjusted for 
other times varying co-variables assumed to have potential 
confounding and or residual effect on trend of outcome 
variable over time.
Further exploratory analyses will be undertaken to look 
at factors predicting time to ‘optimal’ change in C-IMT 
estimated as ‘getting worse.’
Survival plots will be used to estimate time since entry 
into the study until ‘optimal’ change in C-IMT estimated as 
‘getting worse’ within two years since entry into study. This 
will, however, need to be deﬁ  ned using clinically meaning-
ful change.
Between study group comparisons in time to ‘optimal’ 
change in C-IMT will be made using the log rank c2 test. 
Univariate and multivariable Cox’s Proportional hazards 
regression models will be used to identify factors that predict 
‘optimal’ change in C-IMT estimated as ‘getting worse.’
Demographic characteristics will be summarized by 
randomized groups and p-values will be presented describ-
ing associations with these. In addition, all serious adverse 
events will be reported by study arms together with number 
of patients and number of events.
Secondary endpoint is to assess the change in:
• hs-CRP
  To avoid the potential for misclassiﬁ  cation because of 
an exogenous acute-phase stimulus, data from patients 
with either a baseline or two years hs-CRP value   3 SD 
above the mean value will be analyzed and data will be 
presented both including and excluding this from analysis 
on a priori basis.81
• Lipid  parameters
   • TC
   • HDL cholesterol
   • LDL cholesterol
   • TG
   •  HDL cholesterol:TC
•  Apolipoproteins
   •  APO B
   •  APO A1
   •  APO B/APO A1
•  Safety variablesVascular Health and Risk Management 2009:5 297
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All these secondary endpoints will be assessed from 
baseline to study time points by rosuvastatin and the placebo 
arms.
All patients who meet the inclusion criteria at baseline 
will form part of the statistical analysis. Data will be ana-
lyzed and presented as both on treatment and intent to treat 
(ITT) methods.
All statistical analysis will be performed using SAS 
statistical software and all p-values presented will be two 
sided.
One interim analysis is planned during the study duration 
and the sample size estimate has taken account of this. Where 
further unplanned interim analyses are performed, how-
ever, p-values will be appropriately adjusted for unplanned 
repeated data analyses.
Planned subgroup analyses
No subgroup analyses are planned for this study.
Interim analyses and stopping rules
An independent data safety monitoring board (DSMB) will 
be established, which will meet initially, after a predeter-
mined number of subjects have completed two months of 
randomized therapy and at every study visit – at 6, 12, 18 
and 24 months. The DSMB will be made up of three exter-
nal, independent experts within the ﬁ  eld of HIV and lipid 
metabolism disorders; two physicians and one statistician.
Stopping rules will be agreed at the ﬁ  rst meeting and will 
include the following.
•  Elevation of creatine kinase  3 times ULN
• ALT   3 times ULN
•  Intolerable myalgia or other intolerable side effects (see 
ACTG grading; Appendix 2).
Criteria for termination of the trial
The sponsor or investigator may terminate either part of, 
or the entire study for safety or administrative reasons. 
A written statement fully documenting the reasons for such 
a termination will be provided to the Ethics Committee and 
the Regulatory Authority as appropriate.
Adverse events
Deﬁ  nitions
An adverse event is any untoward medical occurrence in a 
subject administered a pharmaceutical product and which 
does not necessarily have a casual relationship with the study 
treatments. An adverse event can, therefore, be any unfavor-
able and unintended sign (including an abnormal laboratory 
ﬁ  nding), symptom, or disease temporally associated with 
the use of a medicinal (investigational) product, whether 
or not considered related to the medicinal (investigational) 
product.
Adverse events observed by the investigator, or reported 
by the subject, and any remedial action taken, will be 
recorded in the subject’s CRF and should be veriﬁ  able in 
the subject’s notes throughout the study. The nature of each 
event, time of onset after drug administration, duration and 
severity will be documented together with the investigator’s 
opinion of the causal relationship to the treatment (unrelated, 
unlikely, possible, probable and deﬁ  nite).
All subjects experiencing adverse events, whether con-
sidered associated with the use of the study medication or 
not, must be monitored until the symptoms subside and any 
clinically relevant changes in laboratory values have returned 
to baseline, or until there is a satisfactory explanation for the 
changes observed.
Procedures such as surgery should not be reported as 
adverse events. However, the medical condition for which 
the procedure was performed should be reported if it meets 
the deﬁ  nition of an adverse event. For example, an acute 
appendicitis that begins during the adverse event reporting 
period should be reported as the adverse event and the result-
ing appendectomy noted on the CRF. Planned procedures, 
such as surgery planned prior to the subject’s enrolment into 
the study, need not be reported as adverse events if these are 
documented as planned at the screening visit.
Clinically signiﬁ  cant changes in physical examination 
and blood safety proﬁ  les should also be recorded as adverse 
events.
Serious adverse events (SAEs)
An SAE is any untoward medical occurrence that at any 
dose:
•  Results in death
•  Is life threatening
•  Requires in patient hospitalization or prolongation of 
existing hospitalization
•  Results in persistent or signiﬁ  cant disability/incapacity
•  Is a congenital anomaly/birth defect.
All SAEs must be reported immediately, except for those 
SAEs which the protocol or other document (eg, Investigator 
Brochure) identiﬁ  ed as do no need reporting.
The SAEs should be reported immediately to the principal 
investigator (within 24 hours of a member of the study team 
becoming aware of the event). An SSAT SAE form should 
be completed, and an assessment of whether the SAE is a Vascular Health and Risk Management 2009:5 298
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Suspected Unexpected Serious Adverse Reaction (SUSAR) 
conducted.
The principal investigator is responsible for determin-
ing whether the SAE is a SUSAR and for reporting this in 
accordance with Good Clinical Practice (GCP) and applicable 
regulatory requirements.
Administrative procedures
Ethics approval
The study protocol, subject information and consent form, 
the Investigator Brochure, available safety information, 
subject recruitment procedures (eg, advertisements), infor-
mation about payments and compensation available to the 
subjects and documentation evidencing the investigator’s 
qualiﬁ  cations should be submitted to the Ethics Committee 
for ethical review and approval according to local regula-
tions, prior to the study start. Any changes, which may 
need to be made, will be submitted in the form of numbered 
and dated protocol amendments in accordance with local 
regulations.
Regulatory notiﬁ  cation
As required by local regulations, approval of the appro-
priate regulatory bodes will be obtained, prior to study 
initiation.
Indemnities
The sponsor (St Stephen’s AIDS Trust) has taken out 
appropriate insurance for non-negligence harm for the trial. 
Negligence harm is covered by Chelsea and Westminster 
Hospital NHS Foundation Trust.
Publication policy
A whole or part of this study data will be communicated, 
orally presented and/or published in appropriate scientiﬁ  c 
journals. Full anonymity of subject’s details will be 
maintained throughout. Subjects wanting to see the results of 
the trial can request a copy of the article from the investigators 
once it has been published.
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Abbreviations
AEs, adverse events; AHA, American Heart Association; 
APO, apolipoprotein; C-IMT, carotid intima-media 
thickness; CAMs, cell adhesion molecules; cART, com-
bined antiretroviral therapy; CDC, Centers for Disease 
Control; CRF, case report form; CRP, C reactive protein; 
CV, cardiovascular; CVD, cardiovascular disease; FRS, 
Framingham risk score; HDL, high-density lipoprotein; 
HIV, human immunodeﬁ  ciency virus; HIV-IP, HIV-infected 
patients; hs-CRP, highly sensitive C reactive protein; JBS, 
Joint British Societies; KLF2, Kruppel-like factor 2; LDL, 
low-density lipoprotein; LOCF, last observation carried for-
ward; NNRTI, non-nucleoside reverse transcriptase inhibitor; 
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitors; PPARs, peroxisome proliferator-activated recep-
tors; SAE, serious adverse event; TC, total cholesterol; TG, 
triglycerides; ULN, upper limit of normal.
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